Protocol Tip of the Week
If you're using a sleep tracker or a questionnaire like the Insomnia Severity Index to "optimize" your sleep, cross-check your mood first — self-reported insomnia in older adults is frequently a proxy for undiagnosed anxiety or depression, not a standalone sleep architecture problem. Fix the confound before you start stacking magnesium glycinate and melatonin. Objective data (actigraphy, or real PSG if you're serious) beats a questionnaire every time.Study 1: The Metabolic Dial You're Already Hacking Is Also Running Your Placenta
Researchers looked at placental tissue from women with gestational diabetes and found a disrupted AMPK/mTOR axis tracking with ferroptosis — iron-dependent cell death — in placental cells (PMID: 42868626). Chronic hyperglycemia suppressed AMPK signaling, mTOR activity shifted, and the tissue showed more oxidative, iron-driven cell death than in normoglycemic controls.Why this matters beyond obstetrics: AMPK/mTOR isn't some biohacker-exclusive switch you flip with fasting or metformin — it's a conserved cellular stress sensor that governs tissue survival everywhere, including organs you don't think about optimizing. This study is a clean reminder that insulin resistance and chronic hyperglycemia aren't just "diabetes risk," they're actively degrading AMPK-dependent protective signaling in real tissue, with downstream consequences (here, oxidative cell death) that have nothing to do with blood sugar numbers on paper.
Caveat, and it's a real one: this is observational human tissue analysis, not an intervention trial. We don't know if restoring AMPK activity (pharmacologically or behaviorally) prevents the ferroptosis — correlation, not causation. Don't read this as "fasting fixes placentas." Read it as more evidence that insulin sensitivity is a systemic variable, not an organ-specific one.
Study 2: Real Human Rapamycin Data Exists — It's Just Not Where You're Looking
A transcriptomic and proteomic profiling study of mTOR-related epilepsy (mTORopathies like tuberous sclerosis and focal cortical dysplasia) mapped out the molecular signatures driving these conditions (PMID: 42862573). This patient population already takes rapalogs (rapamycin/everolimus) chronically and clinically — it's FDA-approved, not off-label speculation.Here's the point the longevity crowd keeps missing: everyone citing mouse ITP lifespan data for rapamycin dosing protocols is ignoring a goldmine of actual human long-term safety and efficacy data sitting in neurology clinics. TSC and epilepsy patients on years of mTOR inhibition are a real-world cohort for immune function, metabolic markers, and wound healing effects — the stuff biohackers worry about with their weekly 6mg rapamycin pulses. This profiling study won't hand you a dosing protocol, but it's a step toward identifying biomarkers that predict who responds to mTOR inhibition and at what degree of pathway suppression. If you're serious about rapamycin and longevity, start reading TSC cohort follow-ups instead of extrapolating from C. elegans.